Hsiri Therapeutics is a pharmaceutical company based in Media, PA, dedicated to discovering and developing therapies for infections caused by drug-resistant bacteria and drug-resistant fungal diseases. Their research focuses on three main areas: mycobacterial infections, bacterial infections resistant to current treatments, and fungal infections resistant to drugs. With research concepts originating from Professor Marvin Miller at the University of Notre Dame, Hsiri Therapeutics has received support from the Department of Defense and the National Institutes of Health. Their discovery and research laboratories are located in South Bend, IN, with strong research collaborations in Bozeman, MT, and Singapore.
Under the leadership of Chairman and CEO William Claypool, M.D., Hsiri Therapeutics aims to address the significant unmet medical need in the market by developing compounds targeting tuberculosis, non-tuberculous mycobacterial infections, drug-resistant bacterial infections, and drug-resistant fungal infections. With a team of experienced professionals, including Chief Scientific Officer Marvin Miller, Ph.D., Chief Financial Officer Ivan Joseph, MBA, and Chief Operating Officer Carrie Frey, MSC, MBA, Hsiri Therapeutics is committed to advancing antibiotic research and discovering new therapies for drug-resistant infections.
Generated from the website